Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome
- 31 December 2004
- journal article
- case report
- Published by Elsevier in The Journal of Pediatrics
- Vol. 145 (6) , 851-855
- https://doi.org/10.1016/j.jpeds.2004.08.001
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathwayProceedings of the National Academy of Sciences, 2003
- Targeted Disruption of Pyrin, the FMF Protein, Causes Heightened Sensitivity to Endotoxin and a Defect in Macrophage ApoptosisPublished by Elsevier ,2003
- The PAAD/PYRIN-Family Protein ASC Is a Dual Regulator of a Conserved Step in Nuclear Factor κB Activation PathwaysThe Journal of Experimental Medicine, 2002
- The InflammasomeMolecular Cell, 2002
- Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorderHuman Molecular Genetics, 2002
- Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean feverGenes & Immunity, 2002
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A New Autosomal Dominant Disorder of Pyogenic Sterile Arthritis, Pyoderma Gangrenosum, and Acne: PAPA SyndromePublished by Elsevier ,1997